The S.E.C. alleged shortcomings in research said to support the drug, and its developer agreed to a $40 million settlement. Some experts wonder why clinical trials have not been stopped.
Category: Clinical Trials
-
F.D.A. Approves a New Antipsychotic Drug
Available antipsychotic treatments work by blocking dopamine receptors. The new drug, Cobenfy, takes a different approach.
-
Three MDMA Studies Are Retracted by Scientific Journal
The psychedelic treatment, for PTSD, was rejected last week by government regulators.
-
F.D.A. Declines to Approve MDMA Therapy, Seeking More Study
The agency said there was insufficient data to allow the use of a treatment for PTSD that involves the drug known as Ecstasy, according to the company seeking approval.
-
Veterans and Lawmakers Lobby for Approval of MDMA Therapy
The F.D.A. is poised to rule on the therapeutic use of the club drug Ecstasy, a potential watershed moment in the nascent field of psychedelic medicine.
-
A Blood Test Accurately Diagnosed Alzheimer’s 90% of the Time, Study Finds
It was much more accurate than primary care doctors using cognitive tests and CT scans. The findings could speed the quest for an affordable and accessible way to diagnose patients with memory problems.
-
Executives Depart Cassava, Maker of Disputed Alzheimer’s Drug
The chief executive and a lead scientist stepped down weeks after a federal grand jury filed fraud charges against a research collaborator.
-
What Parents Should Know About Cord Blood Banking
Millions of parents have paid to bank blood from their infants’ umbilical cords. But storage companies have misled them about the cells’ promise.
-
Promised Cures, Tainted Cells: How Cord Blood Banks Mislead Parents
Families pay thousands of dollars to store their children’s stem cells with the hope of a healthier future. But the cells are rarely useful, and sometimes contaminated.
-
Malaria Vaccine Rollout to Africa Is a Cautionary Tale
After years of delay, millions of malaria vaccines are being supplied to children in Africa. Tens of thousands died waiting.
-
New Drug Approved for Early Alzheimer’s
The drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline in initial stages of the disease but also carry safety risks.
-
Embattled Alzheimer’s Researcher Is Charged With Fraud
Hoau-Yan Wang, a professor at City College, published studies supporting simufilam, now in advanced clinical trials.